A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma

(2016) Tai Hato et al.   Immunotherapy

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice

(2015) Yunching Chen et al.   HEPATOLOGY

MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu

(2015) Dewan M. S. Hossain et al.   IMMUNOLOGY

A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

(2014) H. Y. Lim et al.   CLINICAL CANCER RESEARCH

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

(2014) A. W. Tolcher et al.   CLINICAL CANCER RESEARCH

Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma

(2012) Roniel Cabrera et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

(2011) Bert H. O'Neil et al.   JOURNAL OF CLINICAL ONCOLOGY

A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy

(2011) Tong San Koh et al.   NMR IN BIOMEDICINE

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)

(2009) Hung Huynh et al.   JOURNAL OF HEPATOLOGY

NORE1B Is a Putative Tumor Suppressor in Hepatocarcinogenesis and May Act via RASSF1A

(2008) D. Macheiner et al.   CANCER RESEARCH

Growth factors as therapeutic targets in HCC

(2008) Junji Furuse   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE